Redpin Therapeutics
New York
About Redpin Therapeutics
Redpin Therapeutics operates as a preclinical stage gene therapy company. It develops a proprietary chemogenetics platform for targeted cell therapies that address currently intractable diseases of the nervous system. Its approach integrates powerful principles from synthetic biology, gene therapy, and traditional pharmacotherapy. The company was founded in 2017 and is headquartered in New York.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $17.0M
- Funding stage: M&A
- Last round: Series A (Jan 2021)
- Website: redpinrx.com
- Phone: 9179719655
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/redpin-therapeutics-62079 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.